Fig. 1 · Structure

Documents & Downloads

Febuxostat (TEI-6720)

Cat. No. A10382 CAS 144060-53-7

xanthine oxidase inhibitor

Febuxostat is a non-purine inhibitor of xanthine oxidase (Ki = 1.2 nM).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Febuxostat inhibits xanthine oxidase-dependent urate formation. In a purified-enzyme study at pH 7.4, reported Dixon-plot Ki estimates were 0.96 nM for soluble XO and 0.92 nM for heparin-Sepharose-bound XO. These assay-specific estimates do not establish cellular potency. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
xanthine oxidase Ki 0.6 nM

Febuxostat (TEI-6720) Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Febuxostat (TEI-6720) from 2 published references. In vitro models include purified XO free in solution or immobilized on heparin-Sepharose 6B.

Febuxostat (TEI-6720) In Vitro Studies

In primed murine bone marrow-derived macrophages challenged with cholesterol crystals, febuxostat reduced intracellular uric acid and ROS signals and suppressed inflammatory mediator release at the tested micromolar concentrations. Reduced LDH release accompanied these effects; the findings apply to this stimulation model. [2]

Febuxostat inhibition of soluble and heparin-bound XO

Biochemical assay · Purified XO free in solution or immobilized on heparin-Sepharose 6B (HS6B). [1]

The authors reported similar inhibition constants for soluble and HS6B-bound XO at pH 7.4. These are Dixon-plot estimates from urate formation, not cellular IC50 values or treatment doses.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Urate formation by soluble XOKi 0.96 nM[1]
Urate formation by HS6B-bound XOKi 0.92 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Varied nanomolar febuxostat; xanthine at 10 and 100 μM.
Method
Dixon analysis of initial urate-formation rates; Figure 4 specifies XO or HS6B-XO at 2 mU/ml, 5 mM KPi, pH 7.4, detection at 295 nm.
Reported limits
Figure 4 caption specifies 5 mM KPi and 295 nm, whereas general Enzyme Analysis specifies 50 mM KPi and 292 nm. Values are attributed to Figure 4 without reconciling these reporting differences. Assay duration, inhibitor vehicle and uncertainty of Ki are not given for Figure 4.
Methods and source locations

Compound reported in the paper: Febuxostat; Compound label in the paper: Febuxostat

Compound-level research findings in the reported model; material from the cited study was not an Adooq lot.

Figure 4A–B and caption; Results: Kinetic analysis; Materials and Methods: Materials, Enzyme Analysis and HS6B binding

Urate formation by soluble XO: Dixon plot, two xanthine concentrations. — Figure 4A and caption; Results: Kinetic analysis

Urate formation by HS6B-bound XO: Dixon plot, two xanthine concentrations. — Figure 4B and caption; Results: Kinetic analysis

Cholesterol crystal responses in murine macrophages

Cell-based study · Pam3CSK4-primed bone marrow-derived macrophages from wild-type C57BL/6 mice, challenged with cholesterol crystals. [2]

Febuxostat reduced crystal-induced uric acid and ROS signals and reduced cytokine/chemokine secretion under these conditions. LDH release was reduced, supporting a protective effect in this assay rather than proving general absence of cytotoxicity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Crystal-induced intracellular uric acid and ROS accumulationDirection Reduced by febuxostat (200 μM)[2]
Secreted IL-1β, MCP-1, IL-1α and IL-6 after crystal challengeDirection Dose-dependent suppression reported at 50 and 200 μM; IL-6 at 50 μM has no significance marker in Figure 5F.[2]
Crystal-induced LDH releaseDirection Reduced with 200 μM febuxostat[2]

Literature-Reported Treatment Conditions

Treatment concentration
50 and 200 μM febuxostat for cytokine assays; 200 μM for uric acid, ROS and LDH panels.
Exposure duration
30 min crystal challenge for uric acid/ROS; 6 h for cytokine/chemokine and LDH assays.
Method
Overnight Pam3CSK4 priming (100 ng/mL), followed by cholesterol crystals (1 mg/mL). ROS methods specify 10–15 min inhibitor pretreatment; this interval is not assigned to other endpoints.
Co-treatment
Febuxostat was tested with the priming/crystal challenge. NAC, apocynin and z-VAD-fmk were separate comparator conditions.
Reported limits
Figure 5 vehicle is labeled but its composition is not specified in the read text. Cytokine-assay inhibitor pretreatment interval and exact replicate/well counts are not specified. Macrophage febuxostat supplier/form is not separately stated.
Methods and source locations

Compound reported in the paper: Febuxostat; Compound label in the paper: Febuxostat

Compound-level research findings in the reported model; material from the cited study was not an Adooq lot.

Figure 5A–G and caption; Results: Cholesterol crystals enhance macrophage inflammatory cytokine secretion via XO and ROS; Methods: BMDM, cell stimulation, ROS, uric acid, ELISA, LDH and statistics

Crystal-induced intracellular uric acid and ROS accumulation: Uric acid/uricase assay normalized to protein; fluorescent intracellular ROS assay. Panels represent three independent experiments, mean ± SEM; exact within-experiment n not specified. — Figure 5A–B and caption; Methods: intracellular uric acid and ROS

Secreted IL-1β, MCP-1, IL-1α and IL-6 after crystal challenge: Supernatant ELISA, 6 h. Representative of three independent experiments, mean ± SEM. Vehicle/medium and vehicle/crystal controls; separate ROS-scavenger and caspase-inhibitor comparators. — Figure 5C–F and caption; corresponding Results and Cell stimulation/ELISA methods

Crystal-induced LDH release: LDH release normalized to Triton X-100 lysis reference, with background subtraction; representative of three independent experiments, mean ± SEM. — Figure 5G and caption; Methods: Measurement of LDH

Febuxostat (TEI-6720) In Vivo Studies

In western-diet-fed male ApoE-deficient mice, 12 weeks of febuxostat in drinking water reduced aortic and aortic sinus plaque area. Macrophage infiltration was not significantly reduced. Total cholesterol was unchanged, while HDL increased. [2]

Plaque formation in diet-fed ApoE-deficient mice

Animal study · Male ApoE−/− (B6.129P2-Apoetm1Unc/J) mice on western diet from 8 weeks of age; vehicle-treated ApoE−/− comparator. WT C57BL/6J mice on normal diet served as non-atherosclerotic controls. [2]

Twelve weeks of febuxostat reduced Oil Red O-positive lesion area in aorta and aortic sinus. MOMA-2-positive macrophage area was not significantly reduced. Total cholesterol was unchanged, while HDL increased; the effect should not be described as absence of all lipid effects.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Oil Red O-positive plaque area in aorta and aortic sinusDirection and reported significance Reduced: en face aorta P < 0.05; aortic sinus P < 0.01 versus vehicle-treated ApoE−/− mice.[2]
MOMA-2-positive aortic sinus areaDirection No significant reduction[2]
Plasma total cholesterol and HDLDirection Total cholesterol unchanged; HDL increased.[2]

Conditions shared by the study groups

Route
Oral, drinking water
Frequency
Via drinking water; no discrete dosing frequency specified.
Treatment course
12 weeks
Vehicle
Drinking water; any additional solubilizer is not specified.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Febuxostat-treated ApoE−/− mice
0.027 mg/mL drinking water; described as 2.5 mg/kg/day in Results.
Vehicle-treated ApoE−/− mice on the same western diet; WT normal-diet control is a different genotype/diet baseline.Twelve weeks of febuxostat reduced Oil Red O-positive lesion area in aorta and aortic sinus. MOMA-2-positive macrophage area was not significantly reduced. Total cholesterol was unchanged, while HDL increased; the effect should not be described as absence of all lipid effects.[2]
Febuxostat-treated ApoE−/− mice
Model: Male ApoE−/− (B6.129P2-Apoetm1Unc/J) mice on western diet from 8 weeks of age; vehicle-treated ApoE−/− comparator. WT C57BL/6J mice on normal diet served as non-atherosclerotic controls.
Reported limits: Individual intake and achieved individual dose are not reported in the read methods; 2.5 mg/kg/day is the authors’ description, not a calculated conversion. Randomization and blinding are not described in the read methods.
Methods and source locations

Compound reported in the paper: Febuxostat; Compound label in the paper: Febuxostat

Compound-level research findings in the reported model; material from the cited study was not an Adooq lot.

Figure 2A–D and caption; Table 1 HTML and accompanying Results; Methods: Animal experiments, histology, blood parameters, XO activity and statistics

Oil Red O-positive plaque area in aorta and aortic sinus: Histological area quantification. Aorta n = 10 per group; sinus n = 19 per group, pooled from two independent experiments; mean ± SEM. No numerical effect sizes inferred from scatter plots. — Figure 2B–C and caption; Results: Febuxostat inhibits plaque formation

MOMA-2-positive aortic sinus area: n = 15 per group, pooled from two independent experiments; mean ± SEM. — Figure 2D and caption; corresponding Results

Plasma total cholesterol and HDL: Enzymatic plasma analysis at 12 weeks. Table 1 n = 10 for these parameters, mean ± SEM; HDL P < 0.05 versus vehicle-treated ApoE−/− mice. — Table 1 HTML; Results: Febuxostat inhibits plaque formation; Methods: Blood parameters

Febuxostat-treated ApoE−/− mice · Figure 2A–D and caption; Table 1 HTML and accompanying Results; Methods: Animal experiments, histology, blood parameters, XO activity and statistics

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 144060-53-7
Applications xanthine oxidase inhibitor
Formula C16H16N2O3S
Molecular Weight 316.4
Synonyms TMX 67; TEI-6720
SMILES
CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 60 mg/mL (189.65 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Febuxostat (TEI-6720) Research References

  1. [1] Malik UZ, Hundley NJ, Romero G, et al. Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production Free radical biology & medicine (2011). PMID: 21554948 DOI: 10.1016/j.freeradbiomed.2011.04.004 Source material
  2. [2] Nomura J, Busso N, Ives A, et al. Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice Scientific reports (2014). PMID: 24686534 DOI: 10.1038/srep04554 Source material

Added to your cart

View Cart Checkout
Loading...